Dermavant engineers $160M deal to pay off GlaxoSmithKline milestones, gear up to launch psoriasis cream

Dermavant has never been shy about its dreams to transform dermatology with their topical cream. And the Roivant subsidiary has now found investors just as enthusiastic as they are.

Todd Zavodnick

Marathon Asset Management, NovaQuest Capital Management and a third, unnamed Boston-based investment firm have agreed...

Click to view original post